Equities Analysts Offer Predictions for DNTH FY2025 Earnings

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) – Wedbush lowered their FY2025 earnings per share estimates for shares of Dianthus Therapeutics in a research report issued on Thursday, November 6th. Wedbush analyst L. Chico now forecasts that the company will post earnings per share of ($4.48) for the year, down from their previous estimate of ($3.12). Wedbush currently has a “Outperform” rating and a $46.00 target price on the stock. The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.61) per share. Wedbush also issued estimates for Dianthus Therapeutics’ Q4 2025 earnings at ($1.69) EPS, Q1 2026 earnings at ($0.85) EPS, Q2 2026 earnings at ($0.88) EPS, Q3 2026 earnings at ($0.89) EPS, Q4 2026 earnings at ($0.91) EPS, FY2026 earnings at ($3.53) EPS, FY2027 earnings at ($3.86) EPS, FY2028 earnings at ($3.89) EPS and FY2029 earnings at $1.08 EPS.

DNTH has been the subject of several other research reports. Robert W. Baird lifted their price objective on shares of Dianthus Therapeutics from $50.00 to $67.00 and gave the company an “outperform” rating in a research note on Tuesday, September 9th. Raymond James Financial restated an “outperform” rating and issued a $63.00 price target (up from $56.00) on shares of Dianthus Therapeutics in a report on Tuesday, September 9th. Guggenheim lifted their price target on shares of Dianthus Therapeutics from $92.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, September 9th. Stifel Nicolaus upped their price objective on shares of Dianthus Therapeutics from $52.00 to $65.00 and gave the company a “buy” rating in a report on Friday, September 12th. Finally, Truist Financial initiated coverage on Dianthus Therapeutics in a research note on Tuesday, October 14th. They issued a “buy” rating and a $56.00 target price for the company. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Dianthus Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $61.13.

Dianthus Therapeutics Stock Performance

Shares of DNTH opened at $36.28 on Monday. The firm has a market cap of $1.17 billion, a PE ratio of -10.43 and a beta of 1.56. Dianthus Therapeutics has a 52-week low of $13.36 and a 52-week high of $40.16. The business’s 50 day moving average price is $34.64 and its two-hundred day moving average price is $25.11.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Wednesday, November 5th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.11). Dianthus Therapeutics had a negative net margin of 4,106.04% and a negative return on equity of 33.02%. The business had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.58 million.

Insider Buying and Selling at Dianthus Therapeutics

In other news, CFO Ryan Savitz sold 20,000 shares of Dianthus Therapeutics stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $35.00, for a total transaction of $700,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 16.56% of the company’s stock.

Hedge Funds Weigh In On Dianthus Therapeutics

Several large investors have recently added to or reduced their stakes in DNTH. Vestal Point Capital LP boosted its stake in Dianthus Therapeutics by 88.2% during the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock valued at $59,616,000 after purchasing an additional 1,499,931 shares during the last quarter. RA Capital Management L.P. raised its stake in shares of Dianthus Therapeutics by 53.6% in the first quarter. RA Capital Management L.P. now owns 2,866,733 shares of the company’s stock worth $52,003,000 after purchasing an additional 1,000,333 shares during the last quarter. Octagon Capital Advisors LP lifted its holdings in shares of Dianthus Therapeutics by 11.0% in the first quarter. Octagon Capital Advisors LP now owns 2,341,667 shares of the company’s stock valued at $42,478,000 after purchasing an additional 231,500 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Dianthus Therapeutics by 13.6% during the third quarter. Vanguard Group Inc. now owns 1,642,198 shares of the company’s stock valued at $64,620,000 after buying an additional 196,117 shares during the last quarter. Finally, Alliancebernstein L.P. boosted its position in shares of Dianthus Therapeutics by 14.5% during the second quarter. Alliancebernstein L.P. now owns 1,174,822 shares of the company’s stock valued at $21,887,000 after buying an additional 149,200 shares during the last quarter. Institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.